Navigation Links
World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage
Date:9/24/2008

World Alzheimer's Day 2008 Special Report: New innovative treatment approaches in Alzheimer's disease which involve mechanisms other than a direct attack on amyloid plaques have emerged as the leading candidates in the fight against Alzheimer's in 2008. These approaches were presented at ICAD 2008, the world's leading forum on dementia research. These new developments are discussed in the debut of AlzheimerVideoNews.com, a new website which takes a critical look at the most important news in Alzheimer's research.

Los Angeles, CA (PRWEB) September 23, 2008 -- AlzheimerVideoNews.com debuts with a World Alzheimer's Day 2008 Special Report, discussing the most significant developments which occurred in 2008 in the field of Alzheimer's disease research. The new report, available in both a video news report and in print at http://www.AlzheimerVideoNews.com [AlzheimerVideoNews.com], discusses several innovative therapeutics which address emerging new targets in Alzheimer's disease. These new therapeutics have taken center stage in 2008, after the prominent failure of the anti-amyloid investigational drugs tramiprosate(Alzhemed®, Neurochem) and Flurizan® (Myriad Genetics).

The promising new therapeutic agents discussed at ICAD 2008, the world's leading forum on dementia research, and in scientific publications in 2008, included the antihistamine Dimebon® (Medivation, now licensed to Pfizer); Rember®, a reforumulation of methylene blue (TauRX Therapeutics of Singapore); and a novel, off-label method of perispinal administration of etanercept. These agents are all hypothesized to address non-amyloid targets, including the tau tangles found in the brain(Rember®).

Among these agents etanercept is unique, because it was designed to correct an abnormality in the immune system, identified in Alzheimer's disease, which may affect brain function. This abnormality, an excess of the molecule TNF in the cerebrospinal fluid, is hypothesized to interfere with brain cell communication in patients with Alzheimer's disease and related forms of dementia.

AlzheimerVideoNews.com takes a critical look at the most important news in Alzheimer's research. The http://www.AlzheimerVideoNews.com [AlzheimerVideoNews.com website] includes links to further reports and discussion regarding recent developments in Alzheimer's research. AlzheimerVideoNews.com is sponsored by http://www.nrimed.com [the Institute for Neurological Research, a private medical group, inc. in Los Angeles], which has developed the perispinal etanercept anti-TNF strategy for dementia.

References: Doody, R.S., S.I. Gavrilova, M. Sano, R.G. Thomas, P.S. Aisen, S.O. Bachurin, L. Seely, and D. Hung, Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet, 2008. 372(9634): p. 207-15.

Tobinick, E.L. and H. Gross, Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol, 2008. 8(1): p. 27.

###

Read the full story at http://www.prweb.com/releases/Alzheimers/etanercept/prweb1358314.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. (Report) World Privacy Forum Publishes Red Flag Rule Suggestions for Hospitals and Providers; New FTC-Enforced Rules Go Into Effect Nov. 1, Can Apply to Health Care Providers
2. New Lottery Ticket Envisions a World Free of MS
3. HTH Worldwide to Provide Mobile Healthcare Tool to HRG North Americas Affiliate Program
4. Kopernikus, observing our planet for a safer world
5. Substantial Second Quarter Surge for Angel MedFlight Worldwide Air Ambulance Services
6. WorldHeart Receives Favorable Decision to Continue NASDAQ Listing
7. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
8. Hurricane Ike: World Vision Readies Supplies, Staff, Volunteers for Response
9. IMRISneuro: The iMRI technology of choice among the worlds top ranked hospitals
10. ScentToSleep.com Is Pleased to Announce That the Company Was Featured in the September 15th Issue of Womans World Magazine
11. UNC receives record $181 million grant to evaluate health, poverty and gender programs worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
World Alzheimer's Day 2008 Special Report: New Alzheimer Targets Take Center Stage
(Date:2/20/2017)... ... 20, 2017 , ... Researchers at the University of Pittsburgh School of Medicine ... that may predict response to a particular class of drugs, not just in patients ... The new findings were published in Proceedings of the National Academy of Science. , ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... regulated industries, announced Biscom Document Router (BDR), the first IoT device from Biscom ... diagnostics and imaging. Biscom will debut BDR at HIMSS17 and will ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is pleased ... the company. The new location will triple the size of the previous location while ... town of Sunapee, NH. , “We are excited to expand our footprint to ...
(Date:2/20/2017)... ... ... Chuck E. Cheese’s® and Center for Autism and Related Disorders (CARD) recently announced ... throughout New England, New York and New Jersey to provide children with autism spectrum ... Chuck E. Cheese’s in a sensory-friendly environment. , After a successful pilot run ...
(Date:2/19/2017)... , ... February 19, 2017 , ... The Citadel’s new ... nursing students, is being led by Amelia Joseph, Ph.D. Joseph was engaged by the ... of the nursing department in early 2016. After a nation-wide search, she was selected ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Lexmark International, ... solution that connects Lexmark multifunction printers (MFPs) to EDCO ... leading scanning and indexing software solutions for medical records. ... use a Lexmark MFP at the point of care ... facilities reach HIMSS Stage 7 through state-of-the-art ...
(Date:2/21/2017)... IDAHO FALLS, Idaho , Feb. 21, 2017 /PRNewswire/ ... is has completed a private placement with certain investors ... preferred stock of the Company, Series C Convertible Redeemable ... Stock accrues dividends at an annual rate of 6% ... share.  The Company plans to use the proceeds for ...
(Date:2/21/2017)... SAN JOSE, Calif. , Feb. 21, 2017 ... announced that its Cadence ® Tensilica ® Fusion ... HaLow ™ MAC IP offering. The licensable IP targets ... smart city and industrial applications. M2B leveraged the Fusion F1 ... to run value-added applications like voice trigger, audio identification and ...
Breaking Medicine Technology: